CD14 and acute graft versus host disease: Antonio et al. reported that systemic treatment with G-CSF induces expansion of myeloid cells displaying the phenotype of M-MDSCs (Linlow/negHLA-DR−CD11b+CD33+CD14+), which is the only graft parameter to predict acute GVHD (aGVHD) [25].